# Recombinant Human Keratinocyte Growth Factor to Reduce Oral Mucositis in Hematologic Malignancy Patients Undergoing Peripheral Blood Stem Cell Transplantation After Radiation and High-dose Chemotherapy

> **NCT00041665** · PHASE3 · COMPLETED · sponsor: **Amgen**

## Conditions studied

- Stomatitis

## Interventions

- **DRUG:** Recombinant Human Keratinocyte Growth Factor

## Key facts

- **NCT ID:** NCT00041665
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2013-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00041665

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00041665, "Recombinant Human Keratinocyte Growth Factor to Reduce Oral Mucositis in Hematologic Malignancy Patients Undergoing Peripheral Blood Stem Cell Transplantation After Radiation and High-dose Chemotherapy". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00041665. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*